INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened

• Integra LifeSciences Holdings Corporation (IART) filed a Form 8-K on February 26, 2026 to announce its financial results for the quarter and full year ended December 31, 2025. The company attached a press release as Exhibit 99.1 and included reconciliations of several non-GAAP measures to GAAP results for the quarters and years ended December 31, 2025 and 2024. The filing was signed by Lea Knight, Executive Vice President and Chief Financial Officer.

Key Details

• Press release dated February 26, 2026 announcing Q4 and full-year 2025 financial results (press release attached as Exhibit 99.1).
• Reconciliations provided for multiple metrics (quarters and years ended Dec. 31, 2025 and 2024): GAAP revenues to organic revenues; GAAP net income to adjusted EBITDA; GAAP net income to adjusted net income; GAAP gross profit/margin to adjusted gross profit/margin; GAAP EPS to adjusted EPS; GAAP total debt to net debt; GAAP operating cash flow to free cash flow and adjusted free cash flow conversion.
• Company provided forward-looking guidance for adjusted earnings per diluted share but did not reconcile that guidance to GAAP EPS, stating certain GAAP expense items are highly variable and cannot be predicted with reasonable certainty.

Why It Matters

• Investors get the company’s official quarterly and full-year 2025 results plus detailed reconciliations that show how management adjusts GAAP figures to present “organic” and “adjusted” performance—useful for comparing underlying trends to reported GAAP results.
• The adjusted EPS guidance gives a view of management’s expectations, but because there is no reconciliation to GAAP EPS, investors cannot directly map the guidance to GAAP earnings per share; the company explains unpredictable GAAP items prevent a reliable reconciliation.